Case report

Incisional carcinoma of Mullerian Origin: A case report and review of literature

Sabrina Bedella, Zenas Chang, Cassandra Burt, Mahmoud A. Khalifa, Peter A. Argenta

A R T I C L E   I N F O

Keywords:
- Incisional carcinoma
- Abdominal wall metastases
- Endometrioid carcinoma

A B S T R A C T

Primary incisional carcinoma (PIC) is a rare, delayed complication of surgery, usually attributed to the malignant transformation of endometriosis.

We report a case of incisional carcinoma with nodal metastases in a 55-year-old woman, 18 years after cesarean section. She underwent extirpative surgery, including hysterectomy and bilateral salpingo-oophorectomy, without intraperitoneal disease identified. Adjuvant treatment included sandwiched platinum-based chemotherapy (carboplatin and paclitaxel) and radiation. She remains disease-free 8 months after completing therapy.

We identified 46 additional reported cases. Of these, >90% had undergone an “endometrium-exposing” surgery, most commonly cesarean section; while no cases followed adnexal-only surgery. The median time between antecedent surgery and presentation was 18 years. At presentation, tumors were often large (median 8 cm), and symptomatic with pain (63%) and/or mass (26%). Serum CA125 levels were commonly, albeit slightly, elevated (median 57U/ml (IQR 22–96, Range 6–1690)). Lymph node metastases were common (35%), with most following a vulvar-type spread pattern (inguinal first). Most patients (63%) were treated with chemotherapy +/- radiation. Approximately 50% of patients recurred promptly (median < 6 months), but long-term survival was reported following combined chemotherapy/radiation. Lymph node metastases portended a shorter disease-free interval, with 73% of cases recurring (median 5 months) despite chemotherapy-based treatment.

These data suggest that some incisional carcinomas may result from displacement of healthy endometrium followed by delayed malignant transformation. Chemotherapy-only and radiation-only treatments are attended by modest prognosis. Taken together, these data suggest there is both need and potential avenues for improved prevention, detection, and treatment of this condition.

1. Background

Incisional carcinoma is a rare, delayed surgical complication which is attended by a generally poor prognosis. Incisional carcinoma can occur after surgery for either malignant or benign indications; in the latter case the development is most commonly attributed to the malignant transformation of either endometriosis implants invasive into the surgical scar, or to endometrial tissue displaced during gynecologic or obstetric surgery which can occur in 0.03–1.73% of cases after cesarean section (Adriaanse et al., 2013).

The criteria to diagnose endometriosis-related malignancies was proposed by Sampson in 1925 and includes (1) presence of both benign and malignant endometrial tissue in the tumor, (2) histology compatible with endometrial origin, (3) no other primary tumor sites (Sampson, 1925). In 1953, Scott added a fourth criterion to this list: (4) demonstration of benign endometriosis contiguous with the malignant tissue (Scott, 1953).

Notably, not all suspected cases meet Sampson’s criteria, suggesting that even isolated incisional carcinoma may arise through variable mechanisms. When incisional carcinoma is found in the anterior abdominal wall the differential diagnosis must also include cutaneous metastasis from an ovarian, endometrial, cervical, or non-gynecologic malignancy as well as primary skin adnexal neoplasms. These differential diagnoses would have significant implications for the surgical planning and medical management of these patients.

Given the rarity of the condition, most reports have described only individual cases, making definitive comment on the etiology, evaluation, and optimal management of these patients difficult.

https://doi.org/10.1016/j.gore.2020.100588
Received 17 March 2020; Accepted 18 May 2020
Available online 22 May 2020
2352-5789/ © 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The primary histologic subtypes found in endometriosis-related carcinomas are clear cell carcinoma and endometrioid, though serous, mucinous, mixed, sarcoma and adenocarcinoma not otherwise specified (NOS) have been reported (Modesitt, 2002; Stern, 2001; Bassiouny, 2019; Mihailovici, 2017). Median survival time for carcinoma arising in endometriosis is 35 months (Modesitt, 2002), and for malignant transformation of scar endometriosis is 42 months (Mihailovici, 2017). We present a case of adenocarcinoma NOS found in a cesarean section scar. We then review the relevant literature.

2. Case presentation

A 55-year-old perimenopausal female presented to the emergency department for a syncopal episode. She had noted bruising over her right lower abdomen that had worsened over the three days prior to presenting. Her medical and surgical histories were otherwise unremarkable except for hypertension and one cesarean section 18 years prior to presentation complicated by the development of a mass at the incision identified immediately post-operatively, which was felt to be a seroma, though it had not changed in size, shape, or symptomatology in the ensuing years. A CT scan in the emergency department demonstrated a 6.5 cm lobulated soft tissue mass in the right anterior abdominal wall with associated enhancing 4 and 5 cm masses of the right pelvic sidewall and an enhancing mass in the right inguinal region measuring 3.4 cm (Fig. 1). There were no associated findings in the other pelvic or abdominal organs. A PET scan confirmed high FDG-glucose uptake in all described lesions (SUV max ranged from 3.3 to 21.4), but failed to demonstrate additional lesions or a clear primary site (Fig. 2a, b, and c). Tumor markers were not elevated: Ca125 was 17.2, CEA was 2.0, and CA19-9 was 26.9; and her routine screening was up to date.

A percutaneous biopsy of the anterior-most lesion was obtained and demonstrated malignant cells positive for CK7, PAX-8, WT-1, p53 (strong and diffuse), ER and PR. Combined with morphology, these findings were consistent with a “high-grade adenocarcinoma, favor high-grade serous carcinoma of ovarian, fallopian tube, primary peritoneal origin, or endometrial serous carcinoma.” She underwent cytoreductive surgery including laparotomy, en bloc resection of anterior abdominal wall mass including the underlying fascia and a portion of the rectus muscle, resection of right inguinal, pelvic and para-aortic lymph nodes. Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy were performed, in the absence of overt abnormalities, to exclude the gynecologic organs a primary site. Absorbable mesh was used to facilitate closure of the fascial defect. The patient recovered uneventfully from surgery.

Fig. 1. CT Abdomen/Pelvis: 6.5 cm lobulated soft tissue mass in the right anterior abdominal wall.

Fig. 2. PET CT (A) Mass at the location of the right iliac lymph node chain measuring 4.3x4.0 cm with SUV max of 11.0 and mass of the lower right rectus mass measuring 6.6x3.4 cm with extension into the subcutaneous fat and SUV max of 21.4. (B) 3.5x4.0 cm metabolically active soft tissue mass in the right inguinal region with SUV max of 10.6. (C) Small metabolically active nodule within the distal left rectus muscle just above the pubic symphysis with SUV max of 3.3.
Pathologic evaluation revealed a 6.1 cm high-grade adenocarcinoma with non-clear-cell-morphology (Fig. 3 A) that was noted to be superficial to the abdominal wall fascia and muscle but unattached to the superficial skin. It was located along and within the previous cesarean section scar. Cytoarchitecturally, the tumor was more in keeping with an endometrioid morphology (Fig. 3B) with occasional areas of papillary formation (Fig. 3C). Malignant cells were positive for PAX-8 (Fig. 3D), ER, focally for p63 and p40. Cells were negative for GATA-3, calretinin, D2-40, CK5/6, synaptophysin, and chromogranin. It had metastasized to 2 of 2 right inguinal lymph nodes, and 1 of 14 right pelvic lymph nodes. The uterus, cervix, fallopian tubes, ovaries and omentum were uninvolved by neoplasm and no endometriosis was noted in any site.

The possibility of a primary skin adnexal tumor was considered but was believed unlikely based on the negative staining for calretinin, D2-40 and CK5/6. The tumor morphology was also unsupportive of this possibility. We also excluded the possible origin from ectopic breast tissue (the caudal remnants of the milk ridge) based on the negative staining for GATA-3 with the strong and diffuse staining for PAX-8. The patient was referred for a full dermatologic examination and no suspicious skin lesions were identified.

After discussion of treatment options, the patient elected to receive both chemotherapy and radiation in a sandwiched fashion as previously described by our group (Geller, 2010). She received 3 cycles of carboplatin AUC 6 and paclitaxel (175 mg/m²) with pegfilgrastim administration during each cycle.

Surveillance to date has included clinical and radiologic evaluations (CT scan of the chest, abdomen and pelvis) at the conclusion of treatment and after 3 and 6 months of surveillance. At the time of this report the patient was disease-free at 8 months from completion of therapy (13 months from presentation).

3. Discussion

Our case demonstrates that incisional carcinoma can occur without associated findings of endometriosis and in the absence of overt or microscopic disease in the gynecologic organs. It adds to the 46 English-language prior reports of incisional carcinoma of Mullerian origin (Ovid Medline keywords: carcinoma, incision, abdominal wall, gynecologic surgical procedures) (Modesitt, 2002; Stern, 2001; Bassioumy, 2019; Mihailovici, 2017; Bourdel, 2010; Yan, 2011; Ferrandina, 2016; Park et al., 1999; Archer, 2017; Razzouk, 2007; Miller et al., 1998; Harry, 2007; Achach, 2008; Alberto, 2006; Bats, 2008; Dalnes, 2011; Ijichi, 2014; Jiang, 2015; Li, 2012; Leng, 2006; Madsen et al., 1980; Matsuo, 2009; Matter et al., 2003; Mert, 2012; Omranipour and Najafi, 2010; Rust, 2008; Shalin, 2012; Wei and Huang, 2017; Williams, 2009; Guer, 1996; Markopoulos, 1996; Sawazaki, 2012; Debroz, 2014; Dhaifiri, 2016; Heller, 2014; Liu, 2014; Aust, 2015; Fargas Fabregas, 2014; Gundogdu, 2013; Ruiz et al., 2015; Taburiaux, 2015; Usta, 2014; Lengele et al., 2007). Table 1 summarizes these case reports, and Tables 2 and 3 presents the summary characteristics of the group.

![Fig. 3. Histology of a high grade carcinoma. (A) Glandular morphology suggestive of a high-grade adenocarcinoma with nuclear pleomorphism and abnormal mitoses. (B) Glandular spaces are mostly rounded with a cribriform arrangement suggestive of endometrioid adenocarcinoma. Some of the nuclei showed prominent nucleoli. (C) Focal papillary formations were also noted. (D) Immunohistochemical staining for PAX-8 was strong and diffuse.](image-url)
| Publication | Presenting symptom(s) | Scar type | Histology | Surgical resection extent | Organ involvement (pathology) | Chemotherapy Regimen | Radiation regimen | Time to/location of recurrence | Death |
|-------------|-----------------------|-----------|-----------|---------------------------|-----------------------------|----------------------|------------------|-------------------------------|-------|
| (Bourdel, 2010) | Mass, umbilicus | Clear cell | Mass, umbilicus, right rectus abdominus, partial pubic symphysis, bilateral external iliac LNs, fallopian tubes, ovaries | None | None | 6 cycles paclitaxel & carboplatin | 45 Gy abdominal-pelvic | 6 months | No recurrence at 12 months |
| (Mihailovici, 2017) | Pain, abdominal bloating/swelling | Clear cell | Mass, uterus, cervix, fallopian tubes, ovaries | None | None | 9 cycles platinum-based | None | None | No recurrence at 12 months |
| (Archer, 2017) | Mass, rectus abdominus, uterus, cervix, fallopian tubes, inguinal LNs, lymph nodes | Clear cell | Mass, umbilicus, right rectus abdominus, partial pubic symphysis, bilateral external iliac LNs, fallopian tubes, ovaries | Not evaluated | None | 7 cycles cisplatin-based | 45 Gy abdominal-pelvic | 6 months | No recurrence at 5 years |
| (Ferrandina, 2016) | Abdominal bloating/swelling | Clear cell | Mass, rectus abdominus and fascia, uterus, fallopian tubes, ovaries, inguinal LNs | 7/14 pelvic LNs, 8/11 inguinal LNs | None | 3 cycles neoadjuvant carboplatin & paclitaxel, 3 cycles pegylated liposomal doxorubicin | None | 2 months | No recurrence at 15 months |
| (Yan, 2011) | Pain | Clear cell | Mass | Not evaluated | None | None | None | None | No recurrence at 24 months |
| (Park et al., 1999) | Mass | Clear cell | Mass, uterus, cervix, fallopian tubes, ovaries, omentum | None | None | 50 Gy external beam | None | None | No recurrence at 5 years |
| (Shalin, 2012) | Pain, ulceration | Clear cell | Mass, ovarian cyst, endometrium, iliac LNs | 2/4 iliac LNs | None | 8 cycles cisplatin-based | None | None | No recurrence at 31 months |
| (Miller et al., 1998) | Pain | Clear cell | Mass, uterus, cervix, fallopian tubes, ovaries, omentum | None | None | Whole pelvic RT with boost to the scar | None | None | No recurrence at 5 years |
| (Li, 2012) | Pain | Clear cell | Mass, uterus, cervix, fallopian tubes, ovaries | None | None | 6 cycles paclitaxel & carboplatin | None | None | No recurrence at 8 months |
| (Bats, 2008) | Mass, abdominal bloating/swelling | Clear cell | Mass, uterus, cervix, fallopian tubes, ovaries, omentum, peritoneal biopsies | None | None | 3 cycles neoadjuvant carboplatin & paclitaxel | None | None | No recurrence at 8 months |
| (Alberto, 2006) | Pain | Clear cell | Mass | None | None | 6 cycles taxol & carboplatin | 45 Gy | None | No recurrence at 7 months |
| (Mert, 2012) | Not specified | Clear cell | Clear cell | None | None | 8 cycles neoadjuvant carboplatin & paclitaxel | None | None | No recurrence at 1 month |
| (Madsen et al., 1980) | Pain, abdominal bloating/swelling | Clear cell | Mucinous Mass | None | None | 5500 rads to the abdominal field, 1600 rads to the pelvic field | None | None | No recurrence at 2 years |
| (Matsuo, 2009) | Pain, abdominal bloating/swelling | Clear cell | Endometrioma resection | None | None | 6 cycles docetaxel & carboplatin | None | None | No recurrence at 18 months |

Table 1: Details of Case Reports on Incisional Carcinoma of Mullerian Origin.
| Publication                           | Presenting symptom(s) | Scar type | Histology                      | Surgical resection extent          | Organ involvement (pathology) | Chemotherapy Regimen | Radiation regimen | Time to/location of recurrence | Death       |
|-------------------------------------|-----------------------|-----------|--------------------------------|------------------------------------|------------------------------|----------------------|-------------------|-----------------------------|-------------|
| Matter et al., 2003                 | Pain                  | CS        | Cystadenocarcinoma              | Mass, endometrial biopsy           | None                         | None                 | None              | No recurrence at 18 months   | --          |
| Wei and Huang, 2017                 | Pain, ulceration      | CS        | Clear cell                     | Mass                               | Not evaluated                | None                 | None              | --                          | --          |
| Da Ires, 2011                       | Pain                  | CS        | Endometrioid, serous           | Mass, endometrial biopsy, left iliac LNs | 2/2 left iliac LNs           | 6 cycles carboplatin & paclitaxel | None             | No recurrence at 15 months   | --          |
| (Leng, 2006)                        | Pain                  | CS        | Endometrioid, sarcoma          | Mass, uterus cervix, fallopian tubes, ovaries | Mass                       | 1 cycle cisplatin & ifosfamide | None             | 2 months 17 months          | --          |
| (Rust, 2008)                        | Pain                  | Abdominal hysterectomy, salpingectomy | Mass, uterus cervix, fallopian tubes, ovaries | Not evaluated | None | None | None | -- | -- |
| Omanpour and Najafi, 2010           | Mass                  | Laparotomy for uterine perforation | Papillary serous                  | Mass, uterus, fallopian tubes, ovaries | None                         | 3 cycles neoadjuvant platinum-based chemotherapy, "postoperative chemotherapy" | None                     | No recurrence at 12 months   | --          |
| Ji et al., 2017                     | Pain                  | CS        | Adenocarcinoma                 | Mass, uterus, cervix, fallopian tubes, ovaries, omentum, pelvic para-aortic and inguinal LNs | 11/18 pelvic LNs, 1/9 para-aortic LNs, 2/5 inguinal LNs | 3 cycles neoadjuvant carboplatin & paclitaxel, 3 cycles carboplatin & paclitaxel | None             | Recurrence at 4 months       | --          |
| Jiang, 2015                         | Not specified         | Mass      | Adenocarcinoma                 | Mass, anterior abdominal wall LN, fallopian tubes, ovaries | Not evaluated | None | 4 cycles carboplatin & paclitaxel | None | 6 months 3 months |
| Razouk et al., 2006                 | Pain                  | CS        | Clear cell, endometrioid       | Mass, uterus, cervix, fallopian tubes, ovaries | None; uterine adenomyosis, left ovarian follicular cyst | None | None | No recurrence at 30 months   | --          |
| (Hitti et al., 1990) (Case B)       | Pain                  | CS        | Endometrioid                   | Mass                               | Not evaluated                | None                 | None              | No recurrence at 24 months   | --          |
| (Gucer, 1996)                       | Pain                  | CS        | LAVH                           | Mass, ovaries, pelvic LNs, omentum | Not evaluated | 4/6 cycles carboplatin & paclitaxel | None | -- | -- |
| (Sawazaki, 2012)                    | Pain                  | CS        | Clear cell, endometrioid       | Mass, uterus, fallopian tubes, ovaries, pelvic LNs | None | 3 cycles neoadjuvant carboplatin & paclitaxel | None | RT to abdominal field | -- |
| Stevens et al., 2013                | Mass                  | Clear cell & endometrioid      | Mass, uterus, fallopian tubes, ovaries, pelvic LNs | None | None | Neoadjuvant carboplatin & paclitaxel | None | No recurrence at 17 months   | --          |
| (Taburiaux, 2015)                   | Not Specified         | CS        | Clear cell & endometrioid      | Mass, uterus, fallopian tubes, ovaries, pelvic LNs, omentum | None | Neoadjuvant carboplatin & paclitaxel, adjuvant carboplatin & paclitaxel | None | -- | -- |
| Al (Dhañafi, 2016)                  | Pain                  | CS        | Clear cell                     | Mass, uterus, fallopian tubes, ovaries, omentum, peritoneal samples | None | None | None | No recurrence at 24 months   | --          |
| (Gundogdu, 2013)                    | Mass                  | CS x2     | Clear cell                     | Mass, left fallopian tube, left ovary, pelvic LNs | None | 6 cycles carboplatin & paclitaxel | None | No recurrence at 31 months   | --          |
| (Heller, 2014)                      | Mass                  | CS x3     | Clear cell                     | Mass, left fallopian tube, left ovary, pelvic LNs | Bilateral pelvic LNs | None | None | 5 months | -- |
| (Fargas Fabregas, 2014)             | Pain                  | CS        | Appendectomy                   | Mass, fallopian tubes, ovaries, omentum, iliac LNs, endometrial biopsy | 2 right and 1 left iliac LNs | 6 cycles carboplatin & paclitaxel | None | No recurrence at 10 months   | --          |
| (Ji, 2014)                          | Pain                  | CS        | Clear cell                     | Mass, partial bladder, uterus, fallopian tubes, ovaries, omentectomy, inguinal/ pelvic para-aortic LNs | Bladder, 8/18 inguinal LNs, 18/21 pelvic LNs, 6/6 para-aortic LNs | 3 cycles carboplatin & paclitaxel | None | 12 months | -- |
| Dobroz, 2014                         | Pain                  | CS        | Clear cell                     | Mass, endometrial biopsy           | None; endometrial polyps | None | None | No recurrence at 10 months   | --          |
| (Aust, 2015)                        | Mass                  | CS, LAVH | Clear cell                     | Mass, endometrial biopsy           | 2/48 LNs | 6 cycles carboplatin & paclitaxel | None | No recurrence at 10 months   | --          |

(continued on next page)
3.1. Origin

Primary incisional carcinoma (PIC), that is without overt alternative primary, likely develops by either the malignant transformation of established endometriosis or by the inadvertent surgical translocation of benign endometrial gland cells followed by malignant transformation. While malignant transformation of endometriosis is well described, the current case describes incisional carcinoma in the absence of associated endometriosis or prior malignancy, suggesting the translocation of benign tissue followed by delayed malignant transformation. This hypothesis is supported by the absence of associated pathology in the gynecologic organs, the long latency from antecedent surgical event (cesarean section 18 years prior), and the lateralized lymphatic spread pattern which is reminiscent of vulvar cancer rather than typical intra-abdominal metastatic spread patterns.

Supporting evidence for the translocation hypothesis in our literature review includes that over 90% of patients with PIC had previously undergone procedures with possible endometrial exposure (89% cesarean section and 4% myomectomy). By comparison only 11% had prior hysterectomy and no cases were reported to have followed adnexal surgery alone. The median time interval from potentially-translocating surgery to presentation (N = 41) was 18 years (interquartile range, IQR 15,24) with > 90% of patients having an interval of at least 10 years, which greatly exceeds the anticipated progression-free interval of a missed diagnosis of cancer at the time of primary surgery.

3.2. Presentation

Patient and demographic characteristics are listed in Table 1. The most common presenting symptoms of PIC in the literature review were pain (29/46, 63%) and mass (12/46, 26%). Ulceration of the skin was
3.3. Evaluation and primary treatment

Clinical evaluation should be directed to defining the extent of disease and excluding an alternate primary. It should begin with clinical evaluation of the incision and the inguinal lymph nodes. Computed tomography (CT) or PET scan is appropriate to evaluate for alternate primary as well as to exclude distant/unresectable disease.

Primary complete surgical resection is recommended when feasible, including evaluation of the inguinal nodes given the lower anterior abdominal wall primarily drains into the inguinal nodes (Lengele et al., 2007). Either primary surgery or neoadjuvant chemotherapy followed by interval cytoreduction was attempted in all 47 reported cases. Resection of the primary tumor with at least one nodal basin evaluation was performed in 16/46 (34.8%) cases (Table 4). Nodal metastases were identified in 13/16 (81%) of cases when performed. In cases where no nodes were removed 20/31 cases reported follow-up; there were 8 recurrences diagnosed at a median of 7 months (range 2–24 months), and 12 patients remained without evidence of disease after follow-up of 8–60 months. Taken together, these data suggest that lymph node involvement is common, even when clinically non-suspicious, and suggests that some lymph node assessment is important to staging and treatment planning.

Of the 46 total cases, 32 (69.6%) were clear cell carcinoma, three (6.6%) endometrioid, two (4.3%) serous, one (2.2%) mucinous, one (2.2%) endometrial stromal sarcoma, five mixed (1 clear/serous, 1 endometrioid/serous, 2 clear/endometrioid, 1 endometrioid/sarcoma; 10.9%), and three (6.6%) adenocarcinoma not otherwise specified (NOS).

3.4. Adjuvant treatment and prognosis

There is no current standard of care for treatment of PIC which was reflected by the variability of treatments in our review of the literature. Twelve of the 46 patients (26%) were treated with adjuvant radiation therapy; of these 6 had reported follow-up. Two of these 6 patients (33%) recurred at a median of 5.5 months, while 4 remained without evidence of disease at a median of 24.5 months (range 12–60). Thirty-four patients (74%) had no adjuvant radiation, of which follow-up data was available on 27. Of these 15 (56%) recurred at a median of 6 months (range 2–24 months); of these 7/15 (47%) died of disease at a median of 12 months (range 6–31 months). Twelve of the 27 patients (44%) without radiation were without evidence of disease at a median of 16 months (range 1–48 months).

Twelve of the 46 patients (26%) were treated with adjuvant chemotherapy. Follow up data was available for 23 patients; of these 13 (57%) recurred at a median of 5.5 months (range 2–24 months). Eight of 9 patients (89%) with a reported final disposition had died of their disease at a median of 14.5 months (range 6–31 months). Eighteen of the 46 patients received no adjuvant chemotherapy. Follow-up data as available on 10/18 patients; of these 4 patients experienced recurrence at a median of 6 months (range 5–8 months), while 6 patients remained without evidence of disease at a median of 21 months (range 12–31 months).

Eight patients (exclusive of the present case) were treated with both chemotherapy and radiation. Follow-up data as available on 4/8 patients; 2 recurred at 5 and 6 months respectively, 1 of whom succumbed to disease at 22 months and one who was alive with disease after 7 months. Two of the 4 patients (50%) remained without evidence of disease at 12 and 60 months respectively.

Lymphatic metastases were associated with a particularly poor prognosis. Thirteen of 16 patients (81%) who underwent lymph node dissection had inguinal or pelvic lymph node metastases. All patients with lymph node metastases were referred for adjuvant chemotherapy. Follow up data was available on 11 of these patients; 8 patients (73%) recurred at a median of 5 months (range 2–10 months) with 4/8 (50%) dying of disease at a median of 11.5 months (range 6–22 months). Three patients with nodal metastases were alive without disease at a median of 15 months (range 10–48 months).

4. Conclusions

Incisional carcinoma is a rare but serious complication of surgery. There appears to be at least two mechanisms by which this condition occurs: translocation of benign endometrial tissue, up to decades prior to malignant transformation, and malignant transformation of endometriosis. Irrespective of the origin, diagnosis appears to be delayed with most lesions being clinically palpable at diagnosis illustrating the importance of maintaining a high index of suspicion and suggesting a potential role for earlier evaluation of persistent incisional masses. Lymph node metastases are common and appear to follow a vulvar distribution suggesting evaluation of the inguinal and pelvic lymph nodes basins appears indicated, especially in light of what appears to be a significant detriment to prognosis when nodal metastases are identified. No adjuvant treatment strategy demonstrated clear superiority in review of the literature, with a majority of patients relapsing within 6 months of completing adjuvant therapy; there were however long-term survivors in each treatment strategy. Further research is clearly needed to elucidate the etiology of this condition as well as to optimize treatment.

Consents

Written cm the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Achach, T., et al., 2008. Clear Cell Adenocarcinoma Arising from Abdominal Wall Endometriosis. J. Oncol. 2008, 1–3.
Adriaanse, B.M.E., Natté, R., Hellebrekers, B.W.J., 2013. Scar endometriosis after a caesarean section: a perhaps underestimated complication. Gynecol. Surg. 10 (4), 279–284.
Alberto, V., et al., 2006. Primary abdominal wall clear cell carcinoma arising in a Cesarean section scar endometriosis. Ir. J. Med. Sci. 175 (1), 69–71.

Archer, L., et al., 2017. Not all abdominal wall masses in women are endometriomas or desmoids; endometriosis-associated abdominal wall cancer. ANZ J. Surg. 89 (5), 609–611.

Aust, S., et al., 2015. Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. Wien Klin Wochenschr. 127 (1–2), 62–64.

Bassiony, D., et al., 2019. Endometriosis-associated Ovarian Cancer is a Subset With a More Favorable Outcome and Distinct Clinical-pathologic Characteristics. Int. J. Gynecol. Pathol. 38, 435–442.

Bato, A.S., et al., 2008. Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature. Fertil Steril 90 (4), 1197 e1–e6.

Bourdell, N., et al., 2010. Exclusive nodal recurrence after treatment of degenerated parietal endometriosis. Fertil Steril 93 (6), 2074 e1–6.

Dalenes, D., et al., 2011. Mixed endometrioid and serous carcinoma developing in abdominal wall endometriosis following Cesarean section. Acta Radiol. 52 (5), 587–590.

Debroas, Z., et al., 2014. Clear cell carcinoma derived from an endometriosis focus in a scar after a cesarean section – a case report and literature review. Ginekologia Polska 85, 792–795.

Dhafiri, S., et al., 2016. Reconstruction of Anterior Abdominal Wall defect by Artificial Dermal Mesh after a Wide Excision of Clear Cells Adenocarcinoma arising from Ectopic Endometriosis. Scholars J. Appl. Med. Sci. 4, 5–10.

Fargas Fabregas, F., et al., 2014. Malignant transformation of abdominal wall endometriosis with lymph node metastasis: Case report and review of literature. Gynecol. Oncol. Case Rep. 8, 10–13.

Ferrandina, G., et al., 2016. Endometriosis-associated clear cell carcinoma arising in cesarean section scar: a case report and review of the literature. World J. Surg. Oncol. 14 (1), 300.

Geller, M.A., et al., 2010. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma. Gynecol. Oncol. 118, 19–23.

Gucer, F., et al., 1996. Endometrioid carcinoma arising within a scar endometriosis. Eur. J. Gynaecol. Oncol. 18, 42–43.

Gundogdu, B., et al., 2013. Primary abdominal wall clear cell carcinoma arising from incisional endometriosis. Asian Pacific J. Reprod. 2 (3), 244–247.

Harry, V.X., et al., 2007. Isolated Clear Cell Adenocarcinoma in Scar Endometriosis Mimicking an Incisional Hernia. Obstetr. Gynecol. 110 (2), 469–471.

Heller, D., et al., 2014. Clear Cell Adenocarcinoma of the Abdominal Wall: A Case Report. J. Reprod. Med. 59, 330–332.

Hitti, I., Glasberg, S., Lubics, S., 1999. Clear Cell Carcinoma Arising in Extrasovarian Endometriosis: Report of Three Cases and Review of the Literature. Gynecol. Oncol. 39, 314–320.

Ijichi, S., et al., 2014. Clear cell carcinoma arising from cesarean section scar endometriosis: case report and review of the literature. Case Rep. Obstet. Gynecol. 2014, 642483.

Ishida, G.M., et al., 2003. Clear Cell Carcinoma Arising in a Cesarean Section Scar. Acta Cytologica 47 (6), 1095–1098.

Ji, W., 2017. Serous Adenocarcinoma Arising From Endometriosis in Cesarean Section Abdominal Wall Scar: A Case Report and Literature Review. Int J Clin Exp Pathol 10 (7), 7534–7541.

Jiang, M., et al., 2015. 18F-FDG PET/CT Findings of a Recurrent Adenocarcinoma Arising From Malignant Transformation of Abdominal Wall Endometriosis. Clin. Nucl. Med. 40 (2), 184–185.

Leng, J., et al., 2006. Carcinosarcoma arising from atypical endometriosis in a cesarean section scar. Int. J. Gynecol. Cancer 16, 452–455.

Legele, R., Nyns-Iebets, C., Scalliet, P., 2007. Anatomical bases for the radiological delineation of lymph node areas. Upper limbs, chest and abdomen. Radiother. Oncol. 84 (3), 335–347.

Li, J.Y., 2003. Two- and three-dimensional Doppler ultrasound analysis of abdominal wall clear cell carcinoma. Ultrasound Obstet Gynecol 22 (1), 98–100.

Liu, H., et al., 2014. Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder and lymph node metastasis. World J. Surg. Oncol. 12, 51–55.

Madsen, H., Hansen, P., Andersen, O.P., 1980. Endometrioid carcinoma in an operation scar. Acta Obstet. Gynecol. Scand. 59, 475–476.

Markopoulos, C., et al., 1996. Endometrioid carcinoma arising in a scar of cesarean section. Case report. Eur. J. Gynecol. Oncol. 17 (6), 520–521.

Matsuo, K., et al., 2009. Primary peritoneal clear cell adenocarcinoma arising in previous abdominal scar for endometriosis surgery. Arch Gynecol. Obstet. 280 (4), 637–641.

Matter, M., Schneider, N., McKenzie, T., 2003. Cystadenocarcinoma of the abdominal wall following cesarean section: case report and review of the literature. Gynecol. Oncol. 91, 438–443.

Mert, I., et al., 2012. Clear cell carcinoma arising in the abdominal wall: two case reports and literature review. Am. J. Obstet. Gynecol. 207 (2), 7–9.

Mihailovic, A., et al., 2017. Endometriosis-associated malignant transformation in abdominal surgical scar: A PRISMA-compliant systematic review. Medicine 96 (49), e9136.

Miller, D., Schools, J., Eihen, T., 1998. Clear cell carcinoma arising in extragenital endometriosis in a cesarean section scar during pregnancy. Gynecol. Oncol. 70, 127–130.

Modesit, S.C., et al., 2002. Ovarian and Extravarian Endometriosis-Associated Cancer. Obstet. Gynecol. 100 (4), 788–795.

Omraniour, R., Najafi, M., 2010. Papillary serous carcinoma arising in abdominal wall endometriosis treated with neoadjuvant chemotherapy and surgery. Fertil Steril 93 (4), 1347 e17–8.

Park, S.W., Hong, S.M., Wu, H.G., Hu, S.W., 1999. Clear Cell Carcinoma Arising in a Cesarean Section Scar Endometriosis A Case Report. J. Koren Med. Scie. 14, 217–219.

Razzouk, K., et al., 2007. Mixed Clear Cell and Endometrioid Carcinoma Arising in Parietal Endometriosis. Gynecol. Obstetr. Investigation 63 (3), 140–142.

Ruiz, M.P., Wallace, D.L., Connell, M.T., 2015. Transformation of Abdominal Wall Endometriosis to Clear Cell Carcinoma. Case Rep. Obstetr. Gynecol. 2015, 1–3.

Rust, M.M., et al., 2008. Clear Cell Carcinoma in a Background of Endometriosis: Case Report of a Finding in a Midline Abdominal Scar 5 Years After a Total Abdominal Hysterectomy. Acta Cytologica 52 (4), 475–480.

 Sampson, J.A., 1925. Endometriosis of the ovary arising in endometrial tissue in that organ. Arch. Surg. 10, 1–72.

Sawazuki, H., et al., 2012. Clear cell adenocarcinoma arising from abdominal wall endometriosis mimicking urachal tumor. Urology 79 (6), e84–e85.

Scott, R.B., 1953. Malignant changes in endometriosis. Obstetr. Gynecol. 2 (3), 247.

Shalin, S.C., 2012. Clear cell adenocarcinoma arising from scar endometriosis: a case report and review of the literature. J. Catan. Pathol. 39 (11), 1035–1041.

Stern, R.C., et al., 2001. Malignancy in Endometriosis: Frequency and Comparison of Ovarian and Extravarian Types. Int. J. Gynecol. Pathol. 20, 133–139.

Taburiaux, L., et al., 2015. Endometriosis-Associated Abdominal Wall Cancer: A Poor Prognosis? Int. J. Gynecol. Cancer 25 (9), 1633–1638.

Usta, T.A., et al., 2014. Endometrial stromal sarcoma in the abdominal wall arising from scar endometriosis. J. Obstet. Gynecol. 34 (6), 541–542.

Wei, C.J., Huang, S.H., 2017. Clear cell carcinoma arising from scar endometriosis: A case report and literature review. G J Vi Xia Za Zhi 29 (1), 55–58.

Williams, C., et al., 2009. Primary Abdominal Wall Clear Cell Carcinoma: Case Report and Review of Literature. Anticancer Res. 29, 1591–1593.

Yan, Y., et al., 2011. Malignant transformation of an endometriotic lesion derived from an abdominal wall scar. Int. J. Gynaecol. Obstet. 115 (2), 202–203.